Report Overview

The EU NSCLC Therapeutics market will register a significant CAGR of XX% during the forecast period 2019-2028, currently at USD XX billion in 2019 & expected to reach USD XX billion in 2028

Non-small-cell lung cancer (NSCLC) is a type of lung cancer, which is differentiated from small-cell lung cancer (SCLC) because of the way the tumor cells look under a microscope. The types of NSCLC are diagnosed in the same way but may be treated differently. Lung cancer is the third most common cancer in the EU, and NSCLC represents 8590% of all lung cancers. Smoking is the biggest risk factor for the development of lung cancer. In the EU, there has been a decrease in lung cancer mortality among men, while it is increasing in women this reflects a difference in smoking trends between the sexes



Market Growth Drivers

The rising prevalence of NSCLC across the EU region due to increasing air pollution and smoking habits amongst the people is likely to drive the market over the coming years. Greater adoption and increasing demand for targeted therapies, which is considered to be the foundation of precision medicine due to increasing R&D initiatives, also due to its sophistication in the targeting of cancerous cells, is one of the most prominent factors for the growth of the EU market